• 1
    Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl 86):8160.
  • 2
    Malling HJ, Bousquet J. Subcutaneous immunotherapy for allergic rhinoconjunctivitis, allergic asthma, and prevention of allergic diseases. Clin Allergy Immunol 2008;21:343358.
  • 3
    Calderón MA, Penagos M, Durham SR. Sublingual immunotherapy for allergic Rhinoconjunctivitis, allergic asthma, and prevention of allergic diseases. Clin Allergy Immunol 2008;21:359375.
  • 4
    Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007, Issue 1. Art. No.: CD0011936.
  • 5
    Wilson DR, Torres Lima M, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005;60:412.
  • 6
    Olaguíbel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J Investig Allergol Clin Immunol 2005;15:916.
  • 7
    Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, Huerta J, Passalacqua G et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006;97:141148.
  • 8
    Röder E, Berger MY, de Groot H, Gerth van Wijk R. Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: a systematic review. Pediatr Allergy Immunol 2008;19:197207.
  • 9
    Wahn U, Tabar A, Kuna P, Halken S, Montagut A, de Beaumont O et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009;123:160166.
  • 10
    Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009;123:167173.
  • 11
    Bukantz SC, Bagg AS, Lockey RF. Adverse effects and fatalities associated with subcutaneous allergen immunotherapy. Clin Allergy Immunol 2008;21:455468.
  • 12
    Passalacqua G, Guerra L, Compalati E, Canonica GW. The safety of allergen specific sublingual immunotherapy. Curr Drug Saf 2007;2:117123.
  • 13
    Horak F, Zieglmayer P, Zieglmayer R, Lemell P, Devillier P, Montagut A et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol 2009;124:471477.
  • 14
    Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA). Guideline on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases. London, UK, Nov 2008 Draft CHMP/EWP/18504/2006. Available at: Accessed on 15 March, 2010.
  • 15
    Guidance for Industry. Allergic Rhinitis: Clinical Development Programs for Drug Products. Draft Guidance. Issued in 2000 by the CDER-US Food and Drug Administration. Available at: Accessed on 15 March, 2010.
  • 16
    Jaeger S. Exposure to grass pollen in Europe. Clin Exp Allergy Rev 2008;8:26.
  • 17
    Bodtger U, Poulsen LK, Malling HJ. Retrospective assessment of seasonal allergic symptoms: over-rating but useful. Clin Exp Allergy 2003;33:496500.
  • 18
    Wilson AM, O’Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004;116:338344.
  • 19
    Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007;62:317324.
  • 20
    Clark J, Schall R. Assessment of combined symptom and medication scores for rhinoconjunctivitis immunotherapy clinical trials. Allergy 2007;62:10231028.
  • 21
    Wahn U, Bauer C, Agertoft L, Mélac M, Le Gall M. Agreement of Efficacy Assessments for Five Grass Pollen Sublingual Immunotherapy (SLIT) Tablets in Children and Adolescents with Grass Pollen Rhinoconjunctivitis and with or without Mild Asthma. J Allergy Clin Immunol 2009;123: Supplement, S59.
  • 22
    Day JH, Briscoe MP. The Environmental Exposure Unit: a system to test anti-allergic treatment. Ann Allergy Asthma Immunol 1999;83:8393.
  • 23
    Horak F, Jäger S. Die Wiener Provokations-Kammer (Vienna Challenge Chamber). Eine neue Methode des Allergenexpositionstests. Wien Klin Wochenschr 1987;99:509510.
  • 24
    Day JH, Horak F, Briscoe MP, Canonica GW, Fineman SM, Krug N et al. The role of allergen challenge chambers in the evaluation of anti-allergic medication: an international consensus paper. Clin Exp Allergy Rev 2006;6:3159.
  • 25
    Stübner P, Zieglmayer R, Horak F. A direct comparison of the efficacy of antihistamines in SAR and PAR: randomized, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit – the Vienna Challenge Chamber (VCC). Curr Med Res Opin 2004;20:891902.
  • 26
    Horak F, Stuebner UP, Zieglmayer R, Kavina A, Lemell P. Levocetirizine has a longer duration of action than fexofenadine after single administration. Br J Clin Pharmacol 2005;60:2431.
  • 27
    Horak F, Stübner P, Zieglmayer R, Lemell P, Kavina A, Marschall K et al. Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis. A pharmacodynamic study of onset of action and efficacy. Curr Med Res Opin 2006;22:151157.
  • 28
    Zieglmayer P, Zieglmayer R, Bareille Ph, Rousell V, Salmon E, Horak F. Fluticasone furoate versus placebo in symptoms of grass-pollen allergic rhinitis induced by exposure in the Vienna Challenge Chamber. Curr Med Res Opin 2008;24:18331840.
  • 29
    Horak F, Zieglmayer P, Zieglmayer R, Lemell P, Yao R, Staudinger H et al. A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber. Ann Allergy Asthma Immunol 2009;102:116120.
  • 30
    Donovan JP, Buckeridge DL, Briscoe MP, Clark RH, Day JH. Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure. Ann Allergy Asthma Immunol 1996;77:7480.
  • 31
    Horak F, Stübner P, Berger UE, Marks B, Toth J, Jäger S. Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study. J Investig Allergol Clin Immunol 1998;8:165171.
  • 32
    Horak F, Stübner P, Zieglmayer R, Kavina A, Vrtala S, Valenta R et al. Results of a Double-Blind Placebo-Controlled Study with Purethal Mites after one year of Therapy, Including a Physiological House-Dust Mite Exposure in the Vienna Challenge Chamber. XXIII EAACI Congress June 2004, Amsterdam, Symposium: Modern Immunotherapy.
  • 33
    Krug N, Hohlfeld JM, Larbig M, Buckendahl A, Badorrek P, Geldmacher H et al. Validation of an environmental exposure unit for controlled human inhalation studies with grass pollen in patients with seasonal allergic rhinitis. Clin Exp Allergy 2003;33:16671674.
  • 34
    Didier A, Malling HJ, Worm M, Horak F, Jäger S, Montagut A et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:13381345.
  • 35
    Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:802809.